Fragment Based Drug Discovery: Case Histories and Experiences of Combining Orthogonal Methods
During the webinar, we will introduce the FBDD methodology, and discuss real cases from the pharmaceutical industry, focusing on the use of NMR together with other biophysical techniques. We will show the importance of using orthogonal approaches to improve the quality and the quantity of hits. Moreover we will discuss approaches to progress fragments when X-ray crystal structures are not available.
What to Expect
In this webinar Dr. Ben Davis, Vernalis Research, and Dr. Matteo Pennestri, Bruker Biospin, will discuss the application of Fragment Based Drug Discovery to drug discovery, and the integration of NMR with orthogonal methods for fragment screening and characterisation.
What You Will Learn
- The crucial role of NMR as part of your FBDD tool box.
- Real cases of FBS by NMR and the importance of using orthogonal methods
- The use of NMR guided models to progress fragments when routine X-ray crystal structures are not available
Who Should Attend?
This webinar will be of interest to anyone interested in improving their lead discovery capabilities. This includes pharmaceutical companies, contract research organizations and academia, with and without previous experience in FBDD. Moreover any company which is part of this ecosystem, particularly fragment library vendors and computational chemistry software companies.
Speakers
Dr. Matteo Pennestri
Product Manager, Pharmaceutical Business Unit, Bruker
Dr. Ben Davis
Research Fellow, Vernalis R&D
